CRISPR Gene Editing Technique Featured in Upcoming Myeloma Immunotherapy Trial
A Phase 1 clinical trial that uses the gene editing tool CRISPR to engineer multiple myeloma cellular immunotherapy will soon be underway at the…
News
FDA to Give Priority Review to Darzalex Combinations for Multiple Myeloma
The U.S. Food and Drug Admnistration will give priority review to Darzalex (daratumumab) as an add-on to standard treatments for multiple myeloma patients who cannot…
Researchers Find Faster, Better Approach to Harvesting Stem Cells for Bone Marrow Transplants, Mouse Study Suggests
A single injection of a new drug combination leads to faster and more effective harvesting of blood stem cells from bone marrow donors, a new mouse…
First Patient Dosed in Phase 1 Trial of P-BCMA-101 CAR T-Cell Therapy for Multiple Myeloma
The first patient has been dosed in a Phase 1 trial of P-BCMA-101, a new, more powerful type of CAR T-cell therapy to fight multiple…
Gamida Recruiting Myeloma Patients for Phase 1 Trial of Its Killer Cells-based Therapy
Gamida Cell is enrolling participants in a Phase 1 clinical trial of an immunotherapy for myeloma and non-Hodgkin’s lymphoma that is based on expanding the…
Potential Myeloma Therapy Shows Positive Interim Phase 2 Trial Results, According to Report
Molecular Partners‘ multiple myeloma treatment candidate MP0250 showed positive preliminary safety and effectiveness results in an ongoing Phase 2 clinical study, according to the biopharmaceutical…
Multiple Myeloma Patients Remain On Treatment Far Less than in Clinical Trials, Study Finds
Patients with relapsed or refractory multiple myeloma who are treated with new therapy combinations remain on their treatments far shorter than those participating in clinical…
Empliciti Improves Response to Combo Treatment in Newly Diagnosed Myeloma Patients, Study Finds
Newly diagnosed multiple myeloma patients respond better to treatment when Empliciti (elotuzumab) is added to a combination of Revlimid (lenalidomide) and dexamethasone,…
FDA Extends Xgeva Approval to Include Myeloma Patients with Bone Lesions
The U.S. Food and Drug Administration (FDA) has agreed to extend Xgeva‘s (denosumab) approval to include patients with multiple myeloma who have bone lesions. The…
Dual-targeted CAR T-cell Therapy Shows Promising Anti-tumor Response in Mice
A preclinical study has shown that a new dual-targeting APRIL CAR T-cell therapy appears to be better at eliminating multiple myeloma cells than conventional CAR T-cell…
